{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T13:44:42Z","timestamp":1791812682988,"version":"4.3.4"},"reference-count":87,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004423","name":"World Health Organization","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004423","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004421","name":"World Bank Group","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004421","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000200","name":"United States Agency for International Development","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000200","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011054","name":"Danish International Development Agency","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100011054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Cancer Policy"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.jcpo.2026.100799","type":"journal-article","created":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T06:33:17Z","timestamp":1788503597000},"page":"100799","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Best practices for implementing the WHO Model List of Essential Cancer Medicines: Chile, Kenya, and Thailand"],"prefix":"10.1016","volume":"50","author":[{"given":"Ver\u00f3nica","family":"Vargas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafael","family":"Cortez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darya","family":"Kizub","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sitaporn","family":"Youngkong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaime","family":"Bayona","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jcpo.2026.100799_bib1","unstructured":"IARC, Global Cancer Observatory, (2025). http:\/\/gco.iarc.fr\/ (accessed October 27, 2018)."},{"key":"10.1016\/j.jcpo.2026.100799_bib2","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1093\/annonc\/mdw213","article-title":"ESMO European Consortium Study on the availability, out-of-pocket costs and accessibility of antineoplastic medicines in Europe","volume":"27","author":"Cherny","year":"2016","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.jcpo.2026.100799_bib3","doi-asserted-by":"crossref","first-page":"2633","DOI":"10.1093\/annonc\/mdx521","article-title":"ESMO International Consortium Study on the availability, out-of-pocket costs and accessibility of antineoplastic medicines in countries outside of Europe","volume":"28","author":"Cherny","year":"2017","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.jcpo.2026.100799_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/S2214-109X(22)00376-X","article-title":"Cancer medicines on the WHO Model List of Essential Medicines: processes, challenges, and a way forward","author":"Jenei","year":"2022","journal-title":"Lancet Glob. Health"},{"issue":"8","key":"10.1016\/j.jcpo.2026.100799_bib5","doi-asserted-by":"crossref","DOI":"10.1200\/GO.22.00034","article-title":"Defining essential childhood cancer medicines to inform prioritization and access: results from an international, cross-sectional survey","author":"Denburg","year":"2022","journal-title":"JCO Glob. Oncol."},{"key":"10.1016\/j.jcpo.2026.100799_bib6","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1016\/S1470-2045(21)00463-0","article-title":"Access to cancer medicines deemed essential by oncologists in 82 countries: an international, cross-sectional survey","volume":"22","author":"Fundytus","year":"2021","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.jcpo.2026.100799_bib7","doi-asserted-by":"crossref","first-page":"735","DOI":"10.2471\/BLT.15.163998","article-title":"Essential medicines for cancer: WHO recommendations and national priorities","volume":"94","author":"Robertson","year":"2016","journal-title":"Bull. World Health Organ."},{"key":"10.1016\/j.jcpo.2026.100799_bib8","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1200\/JCO.2015.61.8736","article-title":"Proposing Essential Medicines to Treat Cancer: Methodologies, Processes, and Outcomes","volume":"34","author":"Shulman","year":"2016","journal-title":"JCO"},{"key":"10.1016\/j.jcpo.2026.100799_bib9","series-title":"How to Prioritize Essential Medicines for Cancer","author":"Fojo","year":"2019"},{"key":"10.1016\/j.jcpo.2026.100799_bib10","series-title":"The Selection and Use of Essential Medicines Report of the 22nd WHO Expert Committee","author":"WHO-WG","year":"2019"},{"key":"10.1016\/j.jcpo.2026.100799_bib11","author":"IQVIA","year":"2021","journal-title":"Glob. Oncol. Trends 2021"},{"key":"10.1016\/j.jcpo.2026.100799_bib12","doi-asserted-by":"crossref","DOI":"10.1001\/jama.2022.19459","article-title":"Reforming the World Health Organization\u2019s Essential Medicines List: Essential but Unaffordable","author":"Hwang","year":"2022","journal-title":"JAMA"},{"key":"10.1016\/j.jcpo.2026.100799_bib13","series-title":"Pricing of cancer medicines and its impacts","author":"WHO","year":"2018"},{"key":"10.1016\/j.jcpo.2026.100799_bib14","author":"WHO","year":"2020","journal-title":"WHO Guidel. Ctry. Pharm. Pricing policies"},{"key":"10.1016\/j.jcpo.2026.100799_bib15","series-title":"Health Policy Watch","article-title":"WHO Establishes Group To Advise On Medicine Pricing Policy","author":"WHO","year":"2023"},{"key":"10.1016\/j.jcpo.2026.100799_bib16","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1093\/annonc\/mdt514","article-title":"Selection of oncology medicines in low-and middle-income countries","volume":"25","author":"Bazargani","year":"2014","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.jcpo.2026.100799_bib17","doi-asserted-by":"crossref","first-page":"e144","DOI":"10.1016\/S1470-2045(21)00706-3","article-title":"Essential medicines list in national cancer control plans: a secondary analysis from a global study","volume":"23","author":"Razis","year":"2022","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.jcpo.2026.100799_bib18","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1093\/oncolo\/oyac143","article-title":"Access to and Affordability of World Health Organization Essential Medicines for Cancer in Sub-Saharan Africa: Examples from Kenya, Rwanda, and Uganda","volume":"27","author":"Kizub","year":"2022","journal-title":"Oncologist"},{"key":"10.1016\/j.jcpo.2026.100799_bib19","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2021-053349","article-title":"Global status of essential medicine selection: a systematic comparison of national essential medicine lists with recommendations by WHO","volume":"12","author":"Piggott","year":"2022","journal-title":"BMJ Open."},{"key":"10.1016\/j.jcpo.2026.100799_bib20","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1003944","article-title":"National adaptation and implementation of WHO Model List of Essential Medicines: A qualitative evidence synthesis","volume":"19","author":"Peacocke","year":"2022","journal-title":"PLOS Med."},{"key":"10.1016\/j.jcpo.2026.100799_bib21","doi-asserted-by":"crossref","unstructured":"V.J. Wirtz, H.V. Hogerzeil, A.L. Gray, M. Bigdeli, C.P. de Joncheere, M.A. Ewen, M. Gyansa-Lutterodt, S. Jing, V.L. Luiza, R.M. Mbindyo, H. M\u00f6ller, C. Moucheraud, B. P\u00e9coul, L. R\u00e4go, A. Rashidian, D. Ross-Degnan, P.N. Stephens, Y. Teerawattananon, E.F.M. \u2019t Hoen, A.K. Wagner, P. Yadav, M.R. Reich, Essential medicines for universal health coverage, The Lancet 389 (2017) 403-476. https:\/\/doi.org\/10.1016\/S0140-6736(16)31599-9.","DOI":"10.1016\/S0140-6736(16)31599-9"},{"key":"10.1016\/j.jcpo.2026.100799_bib22","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/23288604.2018.1543537","article-title":"Asia-Pacific Countries Moving Toward Universal Health Coverage","volume":"5","author":"Lin","year":"2019","journal-title":"Health Syst. & Reform."},{"key":"10.1016\/j.jcpo.2026.100799_bib23","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.vhri.2019.04.006","article-title":"The Impact of Price Negotiations on Public Procurement Prices and Access to 8 Innovative Cancer Medicines in a Middle-Income Country: The Case of Mexico","volume":"20","author":"Moye-Holz","year":"2019","journal-title":"Value Health Reg. Issues"},{"key":"10.1016\/j.jcpo.2026.100799_bib24","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1016\/S1470-2045(25)00159-7","article-title":"Analysis of drug consumption and expenditure of WHO essential medicines for cancer in 40 countries and regions between 2012 and 2022: a multinational drug use study","volume":"26","author":"Jiao","year":"2025","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.jcpo.2026.100799_bib25","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/s41256-019-0115-1","article-title":"A synthesis of implementation science frameworks and application to global health gaps","volume":"4","author":"Villalobos Dintrans","year":"2019","journal-title":"Glob. Health Res. Policy"},{"key":"10.1016\/j.jcpo.2026.100799_bib26","article-title":"Health policy triangle framework: Narrative review of the recent literature","volume":"1","author":"O\u2019Brien","year":"2020","journal-title":"Health Policy OPEN"},{"key":"10.1016\/j.jcpo.2026.100799_bib27","series-title":"WHO\u2019s Essential List Implementation: Countries with Best Practices","author":"Bannenberg","year":"2023"},{"key":"10.1016\/j.jcpo.2026.100799_bib28","series-title":"World Bank Group Country Classification by Income Level","author":"The World Bank","year":"2025"},{"key":"10.1016\/j.jcpo.2026.100799_bib29","series-title":"World Development Indicators","author":"The World Bank","year":"2025"},{"key":"10.1016\/j.jcpo.2026.100799_bib30","series-title":"Diagn\u00f3stico del Mercado de Medicamentos en Chile, 2015","author":"Ministry of Health","year":"2017"},{"key":"10.1016\/j.jcpo.2026.100799_bib31","series-title":"Pharmaceutical sales as a share of gross domestic product (GDP) in Thailand from 2017 to 2018, with a forecast until 2024 [ In Statista","author":"Statista","year":"2020"},{"key":"10.1016\/j.jcpo.2026.100799_bib32","author":"WHO","year":"2023","journal-title":"World Bank. Open. Data"},{"key":"10.1016\/j.jcpo.2026.100799_bib33","first-page":"1","article-title":"Expanding Coverage of Oncology Drugs in an Aging, Upper-Middle-Income Country: Analyses of Public and Private Expenditures in Chile","volume":"5","author":"Vargas","year":"2019","journal-title":"J. Glob. Oncol."},{"key":"10.1016\/j.jcpo.2026.100799_bib34","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/0717-6287-48-10","article-title":"A snapshot of cancer in Chile: analytical frameworks for developing a cancer policy","volume":"48","author":"Jimenez de la Jara","year":"2015","journal-title":"Biol. Res."},{"key":"10.1016\/j.jcpo.2026.100799_bib35","series-title":"OECD Reviews of Public Health: Chile: A Healthier Tomorrow","author":"OECD","year":"2019"},{"key":"10.1016\/j.jcpo.2026.100799_bib36","doi-asserted-by":"crossref","DOI":"10.3389\/fpubh.2023.1302640","article-title":"The legal path for priority setting in Chile: a critical analysis to improve health planning and stewardship","volume":"11","author":"Espinoza","year":"2024","journal-title":"Front. Public. Health"},{"key":"10.1016\/j.jcpo.2026.100799_bib37","first-page":"5","article-title":"Mejor Salud para los Chilenos. Fundamentos Sanitarios, Pol\u00edticos y Financieros de la Necesidad y Oportunidad de Hacer una Reforma al Sistema de Salud Chileno","volume":"44","author":"Sandoval","year":"2004","journal-title":"Cuad. M\u00e9dico Soc."},{"key":"10.1016\/j.jcpo.2026.100799_bib38","unstructured":"El Ojo, El lobby farmac\u00e9utico detr\u00e1s de un grupo de asociaciones de pacientes, (n.d.). https:\/\/bigpharma.ojo-publico.com\/articulo\/el-lobby-farmaceutico-detras-de-un-grupo-de-asociaciones-de-pacientes\/ (accessed September 23, 2025)."},{"key":"10.1016\/j.jcpo.2026.100799_bib39","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1080\/23288604.2018.1513267","article-title":"Kenya National Hospital Insurance Fund Reforms: Implications and Lessons for Universal Health Coverage","volume":"4","author":"Barasa","year":"2018","journal-title":"Health Syst. & Reform."},{"key":"10.1016\/j.jcpo.2026.100799_bib40","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s12939-019-1116-x","article-title":"Examining purchasing reforms towards universal health coverage by the National Hospital Insurance Fund in Kenya","volume":"19","author":"Mbau","year":"2020","journal-title":"Int. J. Equity Health"},{"key":"10.1016\/j.jcpo.2026.100799_bib41","article-title":"Financing and Availability of Essential Medicines Before and After Introduction of the National Hospital Insurance Fund Civil Servants and Disciplined Services Medical Scheme At Webuye District Hospital, Kenya","author":"Mecca","year":"2014","journal-title":"Afr. J. Pharmacol. Ther."},{"key":"10.1016\/j.jcpo.2026.100799_bib42","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0119945","article-title":"Policies and Programs to Facilitate Access to Targeted Cancer Therapies in Thailand","volume":"10","author":"Sruamsiri","year":"2015","journal-title":"PLOS ONE"},{"key":"10.1016\/j.jcpo.2026.100799_bib43","first-page":"133","article-title":"Defining the Benefit Package of Thailand Universal Coverage Scheme: From Pragmatism to Sophistication","volume":"9","author":"Tangcharoensathien","year":"2020","journal-title":"Int. J. Health Policy Manag."},{"key":"10.1016\/j.jcpo.2026.100799_bib44","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1017\/S0266462309090709","article-title":"Historical development of health technology assessment in Thailand","volume":"25","author":"Teerawattananon","year":"2009","journal-title":"Int. J. Technol. Assess. Health Care"},{"key":"10.1016\/j.jcpo.2026.100799_bib45","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0274944","article-title":"What are the impacts of increasing cost-effectiveness Threshold? a protocol on an empirical study based on economic evaluations conducted in Thailand","volume":"17","author":"Isaranuwatchai","year":"2022","journal-title":"PLOS ONE"},{"key":"10.1016\/j.jcpo.2026.100799_bib46","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/1744-8603-7-32","article-title":"Government use licenses in Thailand: The power of evidence, civil movement and political leadership","volume":"7","author":"Wibulpolprasert","year":"2011","journal-title":"Glob. Health"},{"key":"10.1016\/j.jcpo.2026.100799_bib47","first-page":"1040","article-title":"Health care reform in Chile: 2005\u20132009","volume":"138","author":"Valdivieso D","year":"2010","journal-title":"Rev. M\u00e9dica De. Chile"},{"key":"10.1016\/j.jcpo.2026.100799_bib48","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1377\/hlthaff.27.3.782","article-title":"Health Prioritization: The Case Of Chile","volume":"27","author":"Vargas","year":"2008","journal-title":"Health Aff."},{"key":"10.1016\/j.jcpo.2026.100799_bib49","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1093\/heapol\/czt054","article-title":"Achieving effective universal health coverage with equity: evidence from Chile","volume":"29","author":"Frenz","year":"2013","journal-title":"Health Policy Plan."},{"key":"10.1016\/j.jcpo.2026.100799_bib50","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.vhri.2018.12.004","article-title":"Managed Entry Agreements: Learnings for Design and Implementation in Light of International Experiences","volume":"20","author":"Fern\u00e1ndez","year":"2019","journal-title":"Value Health Reg. Issues"},{"key":"10.1016\/j.jcpo.2026.100799_bib51","author":"Poblete","year":"2020","journal-title":"Acuerdos De. Riesgo Compart. Para. Medicam. De. alto Costo En. Chile"},{"key":"10.1016\/j.jcpo.2026.100799_bib52","first-page":"698","article-title":"The Chilean experience with national cancer plan and law: a cooperative bridge between the civil society and the government","volume":"10","author":"Quijano","year":"2022","journal-title":"Int. J. Sci. Res. Manag. (IJSRM)"},{"key":"10.1016\/j.jcpo.2026.100799_bib53","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1016\/S1470-2045(21)00484-8","article-title":"Anticipating the COVID-19-related surge in cancer care demand is urgent in Latin America and the Caribbean","volume":"22","author":"Herrera","year":"2021","journal-title":"Lancet Oncol."},{"issue":"10","key":"10.1016\/j.jcpo.2026.100799_bib54","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1016\/S1470-2045(21)00426-5","article-title":"Estimating the impact of the COVID-19 pandemic on diagnosis and survival of five cancers in Chile from 2020 to 2030: a simulation-based analysis","volume":"22","author":"Ward","year":"2021","journal-title":"The Lancet Oncology"},{"key":"10.1016\/j.jcpo.2026.100799_bib55","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2022.100487","article-title":"Letter comments on: \u201cTwelve years of European cancer drug approval\u2014a systematic investigation of the \u2018magnitude of clinical benefit","volume":"7","author":"M\u00fcller","year":"2022","journal-title":"ESMO Open."},{"key":"10.1016\/j.jcpo.2026.100799_bib56","series-title":"Kenya Essential Medicines List 2019","author":"Kenya Ministry of Health","year":"2019"},{"key":"10.1016\/j.jcpo.2026.100799_bib57","series-title":"Kenya Essential Medicines List 2023","author":"Kenya Ministry of Health","year":"2023"},{"key":"10.1016\/j.jcpo.2026.100799_bib58","first-page":"16","article-title":"updating the Essential Drugs List","author":"Kenya","year":"1993","journal-title":"Essent. Drugs Monit."},{"key":"10.1016\/j.jcpo.2026.100799_bib59","series-title":"Kenya National Cancer Treatment Protocols","author":"Kenya Ministry of Health","year":"2019"},{"key":"10.1016\/j.jcpo.2026.100799_bib60","doi-asserted-by":"crossref","first-page":"160s","DOI":"10.1200\/jgo.18.26900","article-title":"Developing a National Cancer Control Plan Through Effective Partnerships: A Case of Kenya National Cancer Control Strategy 2017-2022","volume":"4","author":"Karagu","year":"2018","journal-title":"JGO"},{"key":"10.1016\/j.jcpo.2026.100799_bib61","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0324593","article-title":"Evaluating the impact of the National Health Insurance Fund oncology benefits package and a healthcare workers\u2019 strike on time to cancer treatment initiation in Nairobi County, Kenya: An interrupted time series analysis","volume":"20","author":"Gakunga","year":"2025","journal-title":"PLoS One"},{"key":"10.1016\/j.jcpo.2026.100799_bib62","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1080\/13696998.2018.1484372","article-title":"Pilot study assessing the direct medical cost of treating patients with cancer in Kenya; findings and implications for the future","volume":"21","author":"Atieno","year":"2018","journal-title":"J. Med. Econ."},{"key":"10.1016\/j.jcpo.2026.100799_bib63","doi-asserted-by":"crossref","first-page":"93s","DOI":"10.1200\/jgo.18.57100","article-title":"Mapping Stakeholders to Enhance Coordination of Cancer Prevention and Control: The Kenyan Experience","volume":"4","author":"Karagu","year":"2018","journal-title":"JGO"},{"key":"10.1016\/j.jcpo.2026.100799_bib64","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2024.102894","article-title":"An economic evaluation of breast cancer interventions in Kenya","volume":"77","author":"Hutchinson","year":"2024","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.jcpo.2026.100799_bib65","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1093\/heapol\/czaa189","article-title":"The role of government agencies and other actors in influencing access to medicines in three East African countries","volume":"36","author":"Odoch","year":"2021","journal-title":"Health Policy Plan."},{"key":"10.1016\/j.jcpo.2026.100799_bib66","article-title":"A Review on the Selection of Drugs in Thai Heath Care at National, Pharmaceutical industries and Public Hospital Levels-\u0e01\u0e32\u0e23\u0e17\u0e1a\u0e17\u0e27\u0e19\u0e01\u0e32\u0e23\u0e04\u0e31\u0e14\u0e40\u0e25\u0e37\u0e2d\u0e01\u0e22\u0e32\u0e43\u0e19\u0e1a\u0e23\u0e34\u0e1a\u0e17\u0e02\u0e2d\u0e07\u0e1b\u0e23\u0e30\u0e40\u0e17\u0e28\u0e44\u0e17\u0e22\u0e43\u0e19\u0e23\u0e30\u0e14\u0e31\u0e1a\u0e1b\u0e23\u0e30\u0e40\u0e17\u0e28 \u0e2a\u0e16\u0e32\u0e19\u0e1a\u0e23\u0e34\u0e01\u0e32\u0e23\u0e2a\u0e32\u0e18\u0e32\u0e23\u0e13\u0e2a\u0e38\u0e02\u0e41\u0e25\u0e30\u0e2d\u0e38\u0e15\u0e2a\u0e32\u0e2b\u0e01\u0e23\u0e23\u0e21\u0e22\u0e32","author":"Jitruknatee","year":"2020","journal-title":"J. Health Sci."},{"key":"10.1016\/j.jcpo.2026.100799_bib67","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2015-008671","article-title":"Expanding access to high-cost medicines through the E2 access program in Thailand: effects on utilisation, health outcomes and cost using an interrupted time-series analysis","volume":"6","author":"Sruamsiri","year":"2016","journal-title":"BMJ Open."},{"key":"10.1016\/j.jcpo.2026.100799_bib68","first-page":"S4","article-title":"Guidelines for health technology assessment in Thailand \u2013the development process","volume":"97","author":"Chaikledkaew","year":"2014","journal-title":"J. Med. Assoc. Thail. = Chotmaihet Thangphaet"},{"key":"10.1016\/j.jcpo.2026.100799_bib69","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1017\/S0266462319000321","article-title":"Health technology assessment in Thailand: institutionalization and contribution to healthcare decision making: review of literature","volume":"35","author":"Leelahavarong","year":"2019","journal-title":"Int. J. Technol. Assess. Health Care"},{"key":"10.1016\/j.jcpo.2026.100799_bib70","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.vhri.2018.08.004","article-title":"From research to policy implementation: trastuzumab in early-stage breast cancer treatment in Thailand","volume":"18","author":"Kongsakon","year":"2019","journal-title":"Value Health Reg. Issues"},{"key":"10.1016\/j.jcpo.2026.100799_bib71","doi-asserted-by":"crossref","first-page":"221","DOI":"10.56808\/3027-7922.2371","article-title":"Access to medicines for breast, colorectal, and lung cancer in Thailand","volume":"42","author":"Saerekul","year":"2018","journal-title":"Thai J. Pharm. Sci."},{"key":"10.1016\/j.jcpo.2026.100799_bib72","article-title":"Health reform in the midst of a social and political crisis in Chile, 2019-2020","volume":"6","author":"Bossert","year":"2020","journal-title":"Health Syst. Reform."},{"key":"10.1016\/j.jcpo.2026.100799_bib73","unstructured":"OECD, Enhancing economic performance and well-being in Chile Policy Actions for affordable and accessible pharmaceuticals, 2022. https:\/\/www.google.com\/search?q=Policy+Actions+for+affordable+and+accessible+pharmaceuticals+chile&oq=Policy+Actions+for+affordable+and+accessible+pharmaceuticals+chile&gs_lcrp=EgZjaHJvbWUyBggAEEUYOTIGCAEQRRg80gEINzU1OWowajSoAgCwAgA&sourceid=chrome&ie=UTF-8 (accessed September 23, 2025)."},{"key":"10.1016\/j.jcpo.2026.100799_bib74","series-title":"Participaci\u00f3n de agrupaciones de pacientes en la toma de decisiones en el contexto de la Ley Ricarte Soto","author":"Manr\u00edquez Bergenfreid","year":"2018"},{"key":"10.1016\/j.jcpo.2026.100799_bib75","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.jcpo.2015.12.001","article-title":"Joining forces to overcome cancer: the Kenya cancer research and control stakeholder program","volume":"7","author":"Topazian","year":"2016","journal-title":"J. Cancer Policy"},{"key":"10.1016\/j.jcpo.2026.100799_bib76","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.12688\/f1000research.13180.1","article-title":"Health technology assessment capacity development in low- and middle-income countries: experiences from the international units of HITAP and NICE","volume":"6","author":"Tantivess","year":"2017","journal-title":"F1000Res"},{"key":"10.1016\/j.jcpo.2026.100799_bib77","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1017\/S0266462320000628","article-title":"Real-world data for health technology assessment for reimbursement decisions in Asia: current landscape and a way forward","volume":"36","author":"Lou","year":"2020","journal-title":"Int. J. Technol. Assess. Health Care"},{"key":"10.1016\/j.jcpo.2026.100799_bib78","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.vhri.2018.11.004","article-title":"Revisiting roles of health technology assessment on drug policy in universal health coverage in Thailand: where are we? And what is next?","volume":"18","author":"Tanvejsilp","year":"2019","journal-title":"Value Health Reg. Issues"},{"key":"10.1016\/j.jcpo.2026.100799_bib79","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/S1470-2045(25)00270-0","article-title":"Demystifying the WHO Model Lists of Essential Medicines for cancer care","volume":"26","author":"Trapani","year":"2025","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.jcpo.2026.100799_bib80","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.annonc.2024.12.005","article-title":"ESMO Global Consortium Study on the availability, out-of-pocket costs, and accessibility of cancer medicines: 2023 update","volume":"36","author":"Cherny","year":"2025","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.jcpo.2026.100799_bib81","doi-asserted-by":"crossref","first-page":"S45","DOI":"10.4067\/S0034-98872014001300008","article-title":"Equity in health and health technology assessment in Chile","volume":"142","author":"Espinoza","year":"2014","journal-title":"Rev. Med. De. Chile"},{"key":"10.1016\/j.jcpo.2026.100799_bib82","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1017\/S0266462317000381","article-title":"Visions of stakeholders about instutionalization of health technology assessment in Chile: a qualitative study","volume":"33","author":"Lav\u00edn","year":"2017","journal-title":"Int. J. Technol. Assess. Health Care"},{"key":"10.1016\/j.jcpo.2026.100799_bib83","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1186\/s40545-023-00643-z","article-title":"Expanding access to high-cost medicines under the Universal Health Coverage scheme in Thailand: review of current practices and recommendations","volume":"16","author":"Butani","year":"2023","journal-title":"J. Pharm. Policy Pract."},{"key":"10.1016\/j.jcpo.2026.100799_bib84","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1016\/S1470-2045(21)00463-0","article-title":"Access to cancer medicines deemed essential by oncologists in 82 countries: an international, cross-sectional survey","volume":"22","author":"Fundytus","year":"2021","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.jcpo.2026.100799_bib85","doi-asserted-by":"crossref","first-page":"2340","DOI":"10.1093\/annonc\/mdx310","article-title":"ESMO-magnitude of clinical benefit scale version 1.1","volume":"28","author":"Cherny","year":"2017","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.jcpo.2026.100799_bib86","article-title":"Strategies to achieve fairer prices for generic and biosimilar medicines","volume":"368","author":"Ferrario","year":"2020","journal-title":"BMJ"},{"key":"10.1016\/j.jcpo.2026.100799_bib87","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1007\/s10663-019-09446-5","article-title":"Fair prices for medicines? Exploring competent authorities\u2019 and public payers\u2019 preferences on pharmaceutical policies","volume":"46","author":"Vogler","year":"2019","journal-title":"Empirica"}],"container-title":["Journal of Cancer Policy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213538326001001?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213538326001001?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T12:45:47Z","timestamp":1791809147000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213538326001001"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":87,"alternative-id":["S2213538326001001"],"URL":"https:\/\/doi.org\/10.1016\/j.jcpo.2026.100799","relation":{},"ISSN":["2213-5383"],"issn-type":[{"value":"2213-5383","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Best practices for implementing the WHO Model List of Essential Cancer Medicines: Chile, Kenya, and Thailand","name":"articletitle","label":"Article Title"},{"value":"Journal of Cancer Policy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcpo.2026.100799","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"100799"}}